The estimated Net Worth of Donald R. Jr.Drw Commoditie... is at least $3.44 Million dollars as of 3 August 2021. Donald Commoditie owns over 60,000 units of Aptose Biosciences Inc stock worth over $3,279,773 and over the last 3 years Donald sold APTO stock worth over $157,200.
Donald has made over 1 trades of the Aptose Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Donald sold 60,000 units of APTO stock worth $157,200 on 3 August 2021.
The largest trade Donald's ever made was selling 60,000 units of Aptose Biosciences Inc stock on 3 August 2021 worth over $157,200. On average, Donald trades about 60,000 units every 0 days since 2021. As of 3 August 2021 Donald still owns at least 8,888,275 units of Aptose Biosciences Inc stock.
You can see the complete history of Donald Commoditie stock trades at the bottom of the page.
Over the last 6 years, insiders at Aptose Biosciences Inc have traded over $2,827,381 worth of Aptose Biosciences Inc stock and bought 538,629 units worth $767,189 . The most active insiders traders include Erich Platzer, Bernd R. Seizinger und William G. Rice. On average, Aptose Biosciences Inc executives and independent directors trade stock every 59 days with the average trade being worth of $14,277. The most recent stock trade was executed by Bernd R. Seizinger on 22 September 2023, trading 17,000 units of APTO stock currently worth $53,380.
aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt
Aptose Biosciences Inc executives and other stock owners filed with the SEC include: